Selection of antiresorptive or anabolic treatments for postmenopausal osteoporosis-Reference-Cited by-同舟云学术

Selection of antiresorptive or anabolic treatments for postmenopausal osteoporosis

Published:2008-09 Issue:9 Volume:4 Page:514-523
ISSN:1745-8366
Container-title:Nature Clinical Practice Endocrinology & Metabolism
language:en
Short-container-title:Nat Rev Endocrinol

Author:

Papapoulos Socrates,Makras Polyzois

Publisher

Springer Science and Business Media LLC

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism

Link

http://www.nature.com/articles/ncpendmet0941.pdf

Reference76 articles.

1. Kanis JA (1994) Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: synopsis of a WHO report. WHO Study Group. Osteoporos Int 4: 368–381

2. Bouxsein ML (2005) Determinants of skeletal fragility. Best Pract Res Clin Rheumatol 19: 897–911

3. Seeman E and Delmas PD (2006) Bone quality—the material and structural basis of bone strength and fragility. N Engl J Med 354: 2250–2261

4. Felsenberg D and Boonen S (2005) The bone quality framework: determinants of bone strength and their interrelationships, and implications for osteoporosis management. Clin Ther 27: 1–11

5. Manolagas SC (2000) Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. Endocr Rev 21: 115–137

Cited by 32 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparison of pharmacokinetics, pharmacodynamics, safety, and immunogenicity of teriparatide biosimilar with EU- and US-approved teriparatide reference products in healthy men and postmenopausal women;Osteoporosis International;2022-10-26

2. Ginsenoside Rc Promotes Bone Formation in Ovariectomy-Induced Osteoporosis In Vivo and Osteogenic Differentiation In Vitro;International Journal of Molecular Sciences;2022-05-31

3. Uncovering Hidden Mechanisms of Different Prescriptions Treatment for Osteoporosis via Novel Bioinformatics Model and Experiment Validation;Frontiers in Cell and Developmental Biology;2022-02-08

4. High persistence over two years with denosumab among postmenopausal women with osteoporosis in France: A prospective cohort study;Bone;2021-05

5. Romosozumab in Postmenopausal Korean Women with Osteoporosis: A Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study;Endocrinology and Metabolism;2021-02-28